Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × Glucose × Dermatologic × Clear all

Phase

Status

Recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 2 Plasma cell 1 Dermatologic 1 CNS 1 Breast 1

Conditions

Interventions

pembrolizumab 70 Nivolumab 45 Ipilimumab 28 Specimen Handling 14 Magnetic Resonance Spectroscopy 13 trametinib 12 Cyclophosphamide 12 Biopsy 11 dabrafenib 9 avelumab 9 Radiotherapy 9 fludarabine 8 Radiosurgery 8 CTLA-4 Antigen 8 cemiplimab 7 binimetinib 7 atezolizumab 7 lenvatinib 6 fludarabine phosphate 6 encorafenib 6 durvalumab 6 Interleukin-2 6 Immunoglobulin G 6 Disulfides 6 dostarlimab 5 Paclitaxel 5 Introns 5 Cisplatin 5 Carboplatin 5 Bevacizumab 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05933577 2025-09-24

V940-001

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡